Discussing the Recently Approved Tonmya, a Centrally Acting Non- Opioid Analgesic for the Treatment of Fibromyalgia
- Key learnings from Phase III trials include study design, patient selection, endpoint development, and regulatory engagement to streamline approval
- Pharmacologically targeting non-refreshing sleep can improve pain and address other core symptoms of fibromyalgia
- Evaluating selectivity in pain drug development requires balancing toxicology risk with efficacy to maximize therapeutic potential